Vaccine Handling System Strengthening

Partnership objectives

To build, implement and sustain a central vaccine/pharmaceutical handling system comprising a central temperature-controlled warehouse and supply chain with distributable cold-chain capabilities in the strategic North department, on the premises of the Hôpital Sacré Coeur, Haiti.

The project will strengthen Haiti's vaccine and temperature-controlled pharmaceuticals systems and supply-chain. The project will strengthen Haiti's vaccine and temperature-controlled pharmaceuticals systems and supply-chain. Copyright GSK

What are the health needs and challenges?

It is a well-known fact Haiti’s health system lacks a well-defined, temperature-controlled, cold-chain system evidenced by our operations in the country since January 2010. The country’s lack of a country wide temperature-controlled cold-chain system, with no easily accessible, regional distributed, accessible or redundant locations, prevents and continues to inhibit the acquisition, acceptance of donations and distribution of millions of dollars of needed pharmaceuticals, vaccines and other environmentally controlled substances to support natural disasters and now pandemic cholera epidemics and other disease outbreaks. This known detriment adversely affects NGOs and government health operators across the country during attempts to critically resupply health facilities in time of emergent need. This grant proposal, regionally positioned in a northern strategic location, nearby a major seaport location, would help achieve such a strategic objective and have immediate and lasting impact on supporting NGOs and government systems working to strengthening Haiti’s health care system.

Description of partnership activities and how they address needs and challenges

In partnership with GSK, Project HOPE has recently installed a cold chain facility at Hopital Sacre-Coeur de Milot, the only one of its kind in northern Haiti. The facility includes a refrigeration unit, compressor and other equipment needed to maintain a constant temperature between 2 to 8 degrees Celsius. The cold chain ensures vaccine potency, quality and safety from the moment the vaccine is manufactured until the point it is administered to patients. 

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) Hôpital Sacré Coeur, Haiti, Project HOPE

Type of Partner(s) Academia / Hospitals, NGOs

Therapeutic Focus Women and Children's Health, Non-Communicable Diseases, Vaccine-Preventable Diseases

Disease(s) Cancer, Cervical Cancer, Children's Health, Hepatitis, Influenza, Measles, Meningitis C, Mumps, Paratyphoid fever, Pneumonia, Rabies, Rotavirus, Rubella, Shigella, Typhoid Fever, Yellow Fever

Program Type(s) Availability of Treatment - Patient Safety & Medicines Quality, Health System Infrastructure - Development of Physical Infrastructure, Prevention Programs - Vaccines

Targeted Population(s) Children, General population, Marginalised / Indigenous People, People with low income

Region(s) Latin America & Caribbean

Number of Countries 1

Country(ies) Haiti

Start Date 2014

More information GSK Developing Countries Unit

Anticipated completion date Ongoing